iBusiness
Image default
Top News

WHO: Hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 discontinued

WHO has released a statement confirming that it has accepted Solidarity Trial’s International Steering Committee’s recommendation to halt the trial’s hydroxychloroquine and lopinavir/ritonavir arms.

WHO established the Solidarity Trial to find an effective COVID-19 treatment for patients in critical conditions/hospitalized.

This recommendation came in light of the evidence for hydroxychloroquine vs standard-of-care as well as for lopinavir/ritonavir vs standard-of-care – from this review, the trial results produce little to no reduction in the mortality of COVID-19 patients who have been hospitalized as compared to the standard of care.

WHO also confirms that the ‘decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19’

Source: WHO[Media Release]


South African COVID-19 Information Portal

iBusiness on COVID-19
Protect yourself and others around you


Loading...

Digest

Black Panther’s protagonist, Chadwick Boseman dies 43

Isaac More

Lotto and Lotto Plus Results for Wednesday, 19 August 2020

Isaac More

Powerball Results – Tuesday, 23 June 2020

Lotto Results

Leave a Comment

Comments and ratings are subject to verification and approval. Your email will never be published or be shared with a third-party. See our Privacy Policy for clarity | If you are rating a product please ensure to select a star rating - however, this is optional

* By using this form you agree with the storage and handling of your data by iBusiness.co.za

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK Read More